* Pfizer announces positive top-line results from second
phase 3 trial of oral Xeljanz (tofacitinib citrate) in adults
with psoriatic arthritis
The post BRIEF-Pfizer announces positive top-line results from second Phase 3 oral Xeljanz trial appeared first on NASDAQ.